# Gene Panel Market

> Gene Panel Market Research Report Information By Technique (Amplicon Based Approach and Hybridization Based Approach) By Design (Predesigned Gene Panel and Customized Gene Panel) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.58%
- **2025:** USD 3.56 Billion (2025)
- **Key Players:** Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche AG, QIAGEN N.V., Agilent Technologies, Bio-Rad Laboratories, BGI Genomics, Myriad Genetics

**Report ID:** MRFR/LS/4642-CR · **Pages:** 220 · **Author:** Rahul Gotadki & Snehal Singh · **Last Updated:** June 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/gene-panel-market-6100

---

## Market Summary

## Gene Panel Market Summary

The Global Gene Panel Market size was valued at USD 3.56 Billion in 2025, and the market is projected to grow from USD 4.12 Billion in 2026 to USD 14.03 Billion by 2035, registering a CAGR of 14.58% during the forecast period 2026–2035. This trajectory reflects a structural shift in precision medicine, driven by the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination 90.2, which broadened reimbursement for next-generation sequencing panels across oncology indications [[1]](https://cms.gov). Private insurers have followed suit, reducing out-of-pocket burdens and unlocking repeat testing volumes for multi-gene cancer testing workflows.

A quiet revolution is reshaping diagnostic laboratories worldwide. Legacy single-gene Sanger sequencing is giving way to massively parallel targeted genomic sequencing platforms that interrogate dozens to hundreds of genes simultaneously. The NIH All of Us Research Program alone committed over USD 1.4 Billion toward population-scale genomics, expanding the addressable universe for hereditary disease gene panels and pharmacogenomic profiling [[2]](https://allofus.nih.gov). Full-stack providers are bundling sequencing hardware, bioinformatics pipelines, and clinical reporting into single-vendor solutions — accelerating consolidation across the Gene Panel Market.

North America commanded a 38.95% revenue share of the Gene Panel Market in 2025, anchored by robust payer infrastructure and high oncology gene panel testing adoption. Asia-Pacific stands out as the fastest-growing region at a 15.25% CAGR through 2035, propelled by government-backed genomics programs in China, India, and Japan. Europe holds the second-largest share, benefiting from NHS Genomic Medicine Service expansion and the EU's 1+ Million Genomes Initiative. The decade ahead promises broader accessibility as [next-generation sequencing](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354) panels penetrate community hospitals and emerging economies alike.

## Key Report Takeaways

### • By Product & Services

- Test Kits dominated the Gene Panel Market with a 60.05% revenue share in 2025, reflecting strong demand for ready-to-use targeted genomic sequencing kits across clinical laboratories.
- Testing Services are forecast to expand at a 15.23% CAGR through 2035, driven by outsourced oncology gene panel testing from smaller hospital systems.

### • By Technique

- Amplicon-based workflows captured 65.46% of the Gene Panel Market share in 2025, favored for their cost efficiency in multi-gene cancer testing applications.
- Hybridization capture approaches are poised to grow at a 15.16% CAGR to 2035 as larger panels and hereditary disease gene panels demand higher uniformity of coverage.

### • By Application

- Cancer Risk Assessment accounted for 52.45% of the Gene Panel Market in 2025, reflecting widespread NCCN guideline adoption for tumor profiling.
- Pharmacogenetics is projected to advance at a 15.11% CAGR through 2035, aided by growing preemptive prescribing programs.

### • By End User

- Hospitals & Clinics held a 51.98% share of the Gene Panel Market in 2025, anchored by in-house molecular pathology departments.
- Diagnostic Laboratories are set to grow at a 14.99% CAGR to 2035 as reference labs scale high-throughput next-generation sequencing panels.

### • By Region

- North America led the Gene Panel Market with 38.95% revenue in 2025, supported by favorable CMS reimbursement policies.
- Asia-Pacific is forecast to expand at a 15.25% CAGR to 2035, driven by national genomics initiatives and rising oncology gene panel testing demand.

## Gene Panel Market Size and Forecast (2021–2035)

MRFR's market sizing integrates primary interviews with laboratory directors, procurement managers, and sequencing platform vendors, supplemented by secondary analysis of company filings, CMS claims data, and regional genomics databases. Historical figures (2021–2024) are validated against published revenues of leading manufacturers, while the forecast (2026–2035) employs a bottom-up model calibrated to installed sequencing base, test volumes, and average selling prices across next-generation sequencing panels.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanded payer coverage & reimbursement | ~22% | North America, Europe | Short-term (≤2 yr) | [1] |
| Rising cancer incidence & hereditary screening | ~20% | Global | Medium-term (2–4 yr) | [3] |
| NGS cost reduction & throughput gains | ~17% | Global | Long-term (≥4 yr) | [6] |
| AI-enabled variant interpretation | ~14% | North America, APAC | Medium-term (2–4 yr) | [14] |
| Population-scale genomics initiatives | ~12% | APAC, Europe | Long-term (≥4 yr) | [7] |
| Pharmacogenomic clinical integration | ~9% | North America, Europe | Medium-term (2–4 yr) | [8] |
| Direct-to-consumer genetic awareness | ~6% | North America | Short-term (≤2 yr) | [15] |

### Expanded Payer Coverage and Reimbursement

CMS's National Coverage Determination 90.2 eliminated prior authorization for next-generation sequencing panels in patients with advanced solid tumors, opening a reimbursement channel worth an estimated USD 680 Million annually in Medicare oncology gene panel testing claims [[1]](https://cms.gov). Private payers, including UnitedHealthcare, Aetna, and Cigna, subsequently expanded coverage to include hereditary disease gene panels for breast, ovarian, and colorectal cancer risk assessment. This cascading effect reduced the financial barrier that historically limited targeted genomic sequencing adoption outside academic medical centers and accelerated panel ordering volumes in community oncology practices.

### Rising Cancer Incidence and Hereditary Screening Mandates

The WHO Global Cancer Observatory projects 35 Million new cancer cases annually by 2050, a 77% increase over 2022 levels [[3]](https://gco.iarc.who.int). National screening guidelines from NCCN and ESMO now recommend multi-gene cancer testing for patients meeting family history criteria, moving away from single-gene approaches. In the United States alone, approximately 1.2 Million patients per year qualify for hereditary breast and ovarian cancer panel testing under updated ACMG recommendations, driving sustained demand across the Gene Panel Market [[4]](https://acmg.net).

### NGS Cost Reduction and Throughput Gains

The cost of sequencing a human genome dropped below USD 200 in 2024, and targeted panel costs have fallen proportionally [[6]](https://genome.gov). Illumina's NovaSeq X Plus and MGI's DNBSEQ-T20×2 platforms deliver multi-gene cancer testing at under USD 50 per sample in high-volume laboratory settings. These economics make targeted genomic sequencing viable for routine clinical use rather than specialized research, broadening the installed base for gene panel reagents and consumables. By 2030, MRFR anticipates panel sequencing costs to approach USD 25 per sample, further expanding market penetration.

### AI-Enabled Variant Interpretation

Machine learning algorithms are compressing the variant classification bottleneck that once required weeks of manual curation. Companies such as Tempus and SOPHiA Genetics deploy AI engines that classify variants of uncertain significance with over 92% concordance to expert review panels [[14]](https://nature.com). This automation supports faster turnaround for oncology gene panel testing reports and reduces the dependency on scarce molecular geneticists, enabling smaller laboratories to offer comprehensive hereditary disease gene panels without building large in-house bioinformatics teams.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Negative Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Complex regulatory pathways for IVD panels | ~-10% | Global | Long-term (≥4 yr) | [16] |
| Genomic data privacy concerns | ~-8% | Europe, North America | Medium-term (2–4 yr) | [17] |
| Reimbursement variability across geographies | ~-7% | APAC, South America, MEA | Long-term (≥4 yr) | [5] |
| Shortage of genetic counselors | ~-6% | Global | Medium-term (2–4 yr) | [18] |
| Variant of uncertain significance burden | ~-4% | Global | Short-term (≤2 yr) | [14] |

### Complex Regulatory Pathways for Multi-Gene Panels

FDA's premarket approval and 510(k) pathways were designed for single-analyte diagnostics, creating friction for multi-gene cancer testing panels that interrogate 50 to 500 genes simultaneously. The average time-to-clearance for a next-generation sequencing panel exceeds 14 months, and post-market surveillance requirements add compliance costs of USD 2–5 Million per assay [[16]](https://ec.europa.eu). In Europe, the [In Vitro Diagnostic](https://www.marketresearchfuture.com/reports/in-vitro-diagnostics-market-1165) Regulation (IVDR) transition has further tightened conformity assessment, delaying market entry for several targeted genomic sequencing products and constraining innovation velocity within the Gene Panel Market.

### Genomic Data Privacy and Security Risks

The EU General Data Protection Regulation classifies genomic data as a special category requiring explicit consent and enhanced safeguards. Similar frameworks in California (CCPA/CPRA) and China's Personal Information Protection Law add jurisdictional complexity for laboratories processing hereditary disease gene panels across borders [[17]](https://edpb.europa.eu). High-profile breaches — including the 2023 incident at a major direct-to-consumer genetics company affecting nearly 7 Million profiles — have heightened consumer hesitancy and pressured providers to invest heavily in encryption, de-identification, and secure cloud infrastructure.

### Shortage of Genetic Counselors

The National Society of Genetic Counselors estimates that only 6,000 certified professionals practice in the United States, against a projected need of 12,000 by 2030 [[18]](https://nsgc.org). This workforce gap creates a bottleneck between ordering a next-generation sequencing panel and delivering actionable clinical interpretation to patients. Telegenetics and AI-assisted pre-test counseling platforms are emerging solutions, but adoption remains uneven, particularly in rural and underserved communities where oncology gene panel testing volumes are growing fastest.

## Opportunities

## Gene Panel Market Opportunities

### Pharmacogenomic Prescribing Integration

Preemptive pharmacogenomic testing programs like the St. Jude PG4KDS initiative and Vanderbilt's PREDICT program show that incorporating targeted genomic sequencing into electronic health records reduces adverse medication occurrences by as much as 30% [[8]](https://stjude.org). As health systems mandate pharmacogenomic panels at the point of care, the Gene Panel Market has the potential to earn recurring revenue from medication management processes.

### Newborn Screening Expansion

Pilot studies in the UK, Australia and several US states are testing inherited disease gene panels for additional newborn screening beyond established metabolic assays [[12]](https://genomicsengland.co.uk). The Genomics England Newborn Genomes Programme is sequencing 100,000 newborns and may develop a model that can be replicated to expand the addressable test universe of the Gene Panel Market into the realm of population-level preventive medicine.

### Emerging Market Penetration in Southeast Asia and Africa

The Genome India Project in India and the National GeneBank in China have stimulated regional genomics infrastructure, although Southeast Asian countries and sub-Saharan Africa remain underserved [[7]](https://cngb.org). Low cost amplicon-based multi-gene cancer testing kits for less than USD 100 could unlock large volumes in countries with increasing cancer detection rates but fledgling molecular pathology capacity.

### Liquid Biopsy Convergence

Combining circulating tumor DNA analysis and targeted genomic sequencing panel testing for non-invasive monitoring of oncology gene panel testing. FDA clearances have been secured for Guardant Health's Guardant360 and Roche's FoundationOne Liquid CDx, and next-generation panels are being increasingly built to work with both tissue and liquid biopsy inputs, tripling the testing occasions per patient.

### Data Monetization and Real-World Evidence Platforms

De-identified genomic datasets aggregated from multi-gene cancer testing workflows hold value for pharmaceutical R&D, [clinical trial](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787) matching, and payer outcomes analysis. Companies like Tempus and Flatiron Health have demonstrated that coupling panel testing with analytics platforms generates recurring SaaS-like revenue streams beyond the reagent sale, opening a secondary monetization layer within the Gene Panel Market.

## Future Outlook

## Gene Panel Market Future Outlook

### AI-Driven Autonomous Variant Classification

By 2030, artificial intelligence is expected to automate over 80% of variant classification tasks currently performed by molecular geneticists [[14]](https://nature.com). Large language models trained on curated variant databases — such as ClinVar's 2.5 Million submissions — will compress turnaround for hereditary disease gene panels from weeks to hours. This shift enables high-throughput reference laboratories to process next-generation sequencing panels at scale without proportional workforce expansion, fundamentally reshaping the Gene Panel Market cost structure.

### Platform Economics and Single-Vendor Ecosystems

Leading sequencing companies are consolidating reagents, instruments, informatics, and clinical reporting into integrated platforms. Illumina's Connected Software suite and Thermo Fisher's Ion Torrent Genexus exemplify this trend, offering end-to-end multi-gene cancer testing workflows that reduce hands-on time by up to 60% [[13]](https://investor.illumina.com). Platform lock-in strengthens vendor economics but also lowers barriers for community-scale hospitals to adopt oncology gene panel testing without dedicated bioinformatics staff.

### Liquid Biopsy and Minimal Residual Disease Monitoring

The convergence of circulating tumor DNA panels with established tissue-based targeted genomic sequencing assays is creating longitudinal monitoring paradigms. BloombergNEF projects the liquid biopsy segment to exceed USD 12 Billion globally by 2032 [[11]](https://jco.ascopubs.org). Gene panel providers that adapt their chemistries for cfDNA inputs will capture a share of this adjacent opportunity, extending the Gene Panel Market into post-treatment surveillance and recurrence detection.

### ESG, Equity, and Global Access Mandates

WHO's Essential Diagnostics List and the Lancet Commission on Diagnostics have called for universal access to molecular testing in low- and middle-income countries [[19]](https://who.int). Philanthropic funding from the Gates Foundation and Wellcome Trust is subsidizing targeted genomic sequencing infrastructure across sub-Saharan Africa and South Asia. These equity-driven investments will expand the Gene Panel Market's addressable footprint beyond high-income healthcare systems over the coming decade.

## Segment Insights

## Gene Panel Market Segmentation

### By Product & Services

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Test Kits | 60.05% share (2025) | Standardized multi-gene cancer testing workflows |
| Testing Services | 15.23% CAGR (2026–2035) | Outsourced oncology gene panel testing |
| Others | USD 0.19 Billion (2025) | Bioinformatics software and accessories |

Test Kits continue to dominate the Gene Panel Market as clinical laboratories prefer validated, CE-marked kits that streamline regulatory compliance and reduce assay development timelines. Illumina's TruSight Oncology 500 and QIAGEN's QIAseq targeted genomic sequencing panels represent the leading commercial offerings, serving both academic research and clinical diagnostic applications.

Testing Services are accelerating as smaller hospital networks outsource complex hereditary disease gene panels to centralized reference laboratories. This segment benefits from economies of scale — large commercial labs like Quest Diagnostics and Labcorp process tens of thousands of next-generation sequencing panels monthly, achieving lower per-test costs that smaller in-house operations cannot match.

### By Technique

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Amplicon-Based | 65.46% share (2025) | Low-cost, rapid-turnaround workflows |
| Hybridization Capture | 15.16% CAGR (2026–2035) | Uniform coverage for large panels |
| Others | USD 0.08 Billion (2025) | Emerging probe-based technologies |

Amplicon-based targeted genomic sequencing holds the largest share of the Gene Panel Market because of its speed, simplicity, and lower DNA input requirements — critical advantages in oncology settings where biopsy material is limited. Hybridization capture methods are gaining ground for large panels exceeding 300 genes, where their superior uniformity of coverage reduces false-negative rates in multi-gene cancer testing.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Cancer Risk Assessment | 52.45% share (2025) | NCCN/ESMO guideline mandates |
| Pharmacogenetics | 15.11% CAGR (2026–2035) | Preemptive prescribing programs |
| Others | USD 0.25 Billion (2025) | Rare disease, carrier screening |

Cancer Risk Assessment remains the largest application segment within the Gene Panel Market, driven by guideline-mandated multi-gene cancer testing for hereditary breast, ovarian, colorectal, and prostate cancer syndromes. Pharmacogenetics is the fastest-growing application as health systems recognize that oncology gene panel testing paired with drug-gene interaction data reduces adverse events and optimizes therapeutic outcomes.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals & Clinics | 51.98% share (2025) | In-house molecular pathology labs |
| Diagnostic Laboratories | 14.99% CAGR (2026–2035) | High-volume reference testing |
| Others | USD 0.12 Billion (2025) | Academic research, pharma sponsors |

Hospitals & Clinics lead end-user adoption of the Gene Panel Market through embedded molecular pathology departments that run oncology gene panel testing alongside traditional histopathology. Diagnostic Laboratories represent the fastest-growing channel as next-generation sequencing panels shift toward centralized, high-throughput processing models that leverage automation and targeted genomic sequencing platforms.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.95% revenue share | CMS reimbursement, pharma co-development |
| Europe | USD 0.91 Billion | IVDR compliance, NHS Genomics expansion |
| Asia-Pacific | 15.25% CAGR (2026–2035) | Government sequencing programs, lab buildout |
| South America | 14.12% CAGR (2026–2035) | Public health cancer screening pilots |
| Middle East & Africa | USD 0.14 Billion | Genomic medicine centers of excellence |
| Total | USD 3.56 Billion | — |

The Gene Panel Market exhibits a pronounced geographic concentration, with North America and Europe collectively accounting for over two-thirds of global revenue in 2025. Asia-Pacific is reshaping the competitive landscape through government-funded population genomics programs and rapid laboratory infrastructure buildout. Regional dynamics for next-generation sequencing panels vary considerably based on reimbursement frameworks, regulatory maturity, and oncology burden.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 73% of regional share | CMS NCD 90.2, commercial payer expansion |
| Canada | USD 0.21 Billion | Provincial genomics integration programs |
| Mexico | 13.85% CAGR (2026–2035) | Rising oncology gene panel testing access |

The United States remains the epicenter of the Gene Panel Market, powered by a mature payer ecosystem and concentrated demand from academic medical centers and large reference laboratories. CMS reimbursement for targeted genomic sequencing has expanded to encompass hereditary cancer syndromes, while Canada's provincial health systems are embedding multi-gene cancer testing into cancer care pathways through Canadian Partnership Against Cancer initiatives [[1]](https://cms.gov)[[5]](https://uhcprovider.com).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 23% of regional share | Comprehensive cancer center network |
| United Kingdom | USD 0.17 Billion | NHS Genomic Medicine Service rollout |
| France | 14.78% CAGR (2026–2035) | Plan France Médecine Génomique 2025 |
| Italy | 12% of regional share | National oncology screening programs |
| Spain | USD 0.07 Billion | Regional genomic consortia |
| Nordic Countries | 13.95% CAGR (2026–2035) | Population biobank integration |
| Russia | 5% of regional share | Federal genomics research funding |
| Rest of Europe | USD 0.08 Billion | EU 1+ Million Genomes Initiative |

Europe's Gene Panel Market benefits from coordinated cross-border genomics strategies under the EU's 1+ Million Genomes Initiative and country-specific programs such as Genomics England and France's national genomic medicine plan. The IVDR transition has imposed higher compliance costs on manufacturers of hereditary disease gene panels, but it has also raised quality standards and accelerated clinical adoption of validated next-generation sequencing panels across the continent [[10]](https://digital-strategy.ec.europa.eu)[[16]](https://ec.europa.eu).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 31% of regional share | National GeneBank, BGI ecosystem |
| Japan | USD 0.15 Billion | Cancer Genome Atlas Japan initiative |
| India | 16.10% CAGR (2026–2035) | Genome India Project, rising cancer burden |
| South Korea | 13% of the regional share | K-MASTER precision oncology program |
| ASEAN | 15.42% CAGR (2026–2035) | Laboratory infrastructure investment |
| Rest of Asia-Pacific | USD 0.04 Billion | Emerging academic research centers |

Asia-Pacific's rapid ascent in the Gene Panel Market is driven by ambitious national genomics initiatives. China's BGI-led sequencing infrastructure and India's Genome India Project collectively target over 100,000 whole genomes, generating downstream demand for targeted genomic sequencing panels in clinical settings. Japan's nationwide cancer genomic profiling reimbursement, introduced in 2019, has normalized oncology gene panel testing as standard of care in designated hospitals [[7]](https://cngb.org).

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 53% of regional share | SUS public health system adoption |
| Argentina | USD 0.04 Billion | Private laboratory expansion |
| Rest of South America | 13.50% CAGR (2026–2035) | Cancer screening pilot programs |

Brazil leads South American demand for multi-gene cancer testing through its Sistema Único de Saúde (SUS) public health framework, which has begun incorporating hereditary cancer panels into national screening guidelines. Argentina's private diagnostic sector is investing in next-generation sequencing panels to serve growing oncology referral volumes from the Southern Cone region [[9]](https://paho.org).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29% of regional share | Saudi Genome Project |
| UAE | USD 0.03 Billion | Dubai genomic medicine hub |
| South Africa | 13.25% CAGR (2026–2035) | Academic research and NGO programs |
| Egypt | 11% of regional share | National Cancer Institute screening |
| Rest of MEA | USD 0.02 Billion | Development-funded laboratory projects |

Saudi Arabia's national genome initiative and the UAE's investment in genomic medicine centers of excellence anchor the Gene Panel Market in the Middle East. Sub-Saharan Africa remains nascent but holds long-term potential as targeted genomic sequencing costs decline and international development organizations fund cancer diagnostic infrastructure [[7]](https://cngb.org)[[9]](https://paho.org).

## Competitive Benchmarking

## Competitive Benchmarking

The Gene Panel Market exhibits medium concentration, with the top five players commanding an estimated 55–62% of global revenue. The Herfindahl-Hirschman Index (HHI) falls in the 1,200–1,600 range, indicating a moderately competitive structure. Full-stack providers that integrate sequencing hardware, panel chemistries, and bioinformatics software hold pricing power, while pure-play reagent firms compete on breadth of hereditary disease gene panels and clinical validation depth.

| Company | Est. Revenue Share Range | Key Offerings for Gene Panel Market | Strategic Positioning |
| --- | --- | --- | --- |
| Illumina, Inc. | ~18–22% | TruSight Oncology 500, TruSight Hereditary Cancer | Dominant platform with broadest installed base |
| Thermo Fisher Scientific | ~14–17% | Ion Torrent Oncomine panels, Genexus system | Integrated benchtop-to-report workflows |
| F. Hoffmann-La Roche AG | ~10–13% | FoundationOne CDx, AVENIO ctDNA panels | Tissue + liquid biopsy convergence |
| QIAGEN N.V. | ~7–10% | QIAseq targeted panels, Clinical Insight | Flexible multi-gene cancer testing portfolio |
| Agilent Technologies | ~5–8% | SureSelect XT panels, Alissa Interpret | Hybridization capture expertise |
| Bio-Rad Laboratories | ~4–6% | Droplet Digital PCR, QX600 platform | Complementary validation technologies |
| BGI Genomics | ~3–5% | MGIEasy panels, DNBSEQ platforms | Cost-competitive APAC-focused provider |
| Myriad Genetics | ~3–5% | myRisk Hereditary Cancer, GeneSight | Direct clinician-facing testing services |
| Invivoscribe, Inc. | ~2–4% | LymphoTrack, SureSeq panels | Hematological malignancy specialization |
| Guardant Health | ~2–4% | Guardant360, GuardantINFORM | Liquid biopsy-first oncology gene panel testing |

## Recent News & Developments

## Recent News & Developments

- [Illumina](https://sapac.illumina.com/techniques/sequencing/dna-sequencing/targeted-resequencing/targeted-panels.html)(March 2025 ): Launched the MiSeq i100 Series with integrated targeted genomic sequencing panel automation, reducing library preparation time by 40% for clinical laboratories [[20]](https://illumina.com).

- [QIAGEN](https://www.qiagen.com/us/products/discovery-and-translational-research/next-generation-sequencing/dna-sequencing/somatic-panels/qiaseq-targeted-dna-panels)( Oct 2025Partnered with the European Society for Medical Oncology (ESMO) to develop standardized next-generation sequencing panels for pan-European clinical trial enrollment [[23]](https://qiagen.com).

## Report Scope

## Gene Panel Market Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Global Gene Panel Market — Test Kits, Testing Services, Techniques, Applications, End Users |
| Study Period | 2021–2035 |
| CAGR (Forecast Period) | 14.58% (2026–2035) |
| Base Year Market Size | USD 3.56 Billion (2025) |
| Forecast Terminal Value | USD 14.03 Billion (2035) |
| Fastest Growing Segment | Testing Services (by product); Pharmacogenetics (by application) |
| Companies Profiled | 10 (Illumina, Thermo Fisher, Roche, QIAGEN, Agilent, Bio-Rad, BGI, Myriad, Invivoscribe, Guardant Health) |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How do turnaround-time differences between amplicon-based and hybridization capture panels affect clinical decision-making in the Gene Panel Market?**
A: Amplicon-based next-generation sequencing panels typically deliver results in 3–5 days, while hybridization capture workflows require 7–10 days. Clinicians managing time-sensitive oncology cases often prefer amplicon methods to initiate targeted therapy faster [6].

**Q: What minimum sequencing depth should laboratories target when validating a new oncology gene panel testing assay?**
A: Most accrediting bodies recommend a minimum of 500× mean coverage for somatic variant detection in multi-gene cancer testing. Laboratories targeting low-frequency variants below 5% allele fraction should aim for 1,000× or higher [4].

**Q: How does reimbursement for hereditary disease gene panels differ between Medicare Advantage and traditional fee-for-service Medicare?**
A: Medicare Advantage plans may apply prior authorization and step-therapy requirements not present in fee-for-service Medicare. CMS local coverage determinations vary by jurisdiction, creating uneven access to targeted genomic sequencing [1].

**Q: What role do companion diagnostic approvals play in shaping the Gene Panel Market competitive dynamics?**
A: FDA companion diagnostic approvals tie specific therapies to validated panels, creating durable revenue streams for approved assay manufacturers. Roche's FoundationOne CDx holds the most companion diagnostic indications among oncology gene panel testing products [22].

**Q: How are direct-to-consumer genetic testing trends influencing clinical-grade multi-gene cancer testing volumes?**
A: Consumer awareness from services like 23andMe drives patient-initiated referrals for clinical hereditary disease gene panels. An estimated 15% of clinical panel orders now originate from consumer test follow-up [15].

**Q: What infrastructure investments are required for a mid-size hospital to launch in-house targeted genomic sequencing services?**
A: A benchtop sequencer, wet-lab buildout, and bioinformatics pipeline typically cost USD 350,000–600,000 upfront. Ongoing reagent and personnel costs average USD 200,000 annually for moderate-volume next-generation sequencing panels [13].

**Q: How might whole-genome sequencing price declines threaten the Gene Panel Market over the next decade?**
A: Panels retain advantages in turnaround time, interpretive simplicity, and regulatory clarity. Even at sub-USD 200 genome costs, oncology gene panel testing remains preferred for actionable clinical decisions requiring validated assays [6].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gene-panel-market-6100*